|
1
|
Binkhathlan Z and Lavasanifar A:
P-glycoprotein inhibition as a therapeutic approach for overcoming
multidrug resistance in cancer: Current status and future
perspectives. Curr Cancer Drug Targets. 13:326–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Breier A, Gibalova L, Seres M, Barancik M
and Sulova Z: New insight into P-glycoprotein as a drug target.
Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar
|
|
3
|
Nooter K and Stoter G: Molecular
mechanisms of multidrug resistance in cancer chemotherapy. Pathol
Res Pract. 192:768–780. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Teodori E, Dei S, Martelli C, Scapecchi S
and Gualtieri F: The functions and structure of ABC transporters:
Implications for the design of new inhibitors of Pgp and MRP1 to
control multidrug resistance (MDR). Curr Drug Targets. 7:893–909.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stein U and Walther W: Cytokine-mediated
reversal of multidrug resistance. Cytotechnology. 27:271–282. 1998.
View Article : Google Scholar
|
|
6
|
Walther W and Stein U: Influence of
cytokines on mdr1 expression in human colon carcinoma cell lines:
Increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin
Oncol. 120:471–478. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stein U, Walther W and Shoemaker RH:
Modulation of mdr1 expression by cytokines in human colon carcinoma
cells: An approach for reversal of multidrug resistance. Br J
Cancer. 74:1384–1391. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stein U, Walther W and Shoemaker RH:
Reversal of multidrug resistance by transduction of cytokine genes
into human colon carcinoma cells. J Natl Cancer Inst. 88:1383–1392.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding L, Chen XP, Zhang ZW, Guan J, Zhang
WG, Wang HP, Wang ZH and Li CL: Synergistic effect of bromocriptine
and tumor necrosis factor-alpha on reversing hepatocellular
carcinoma multidrug resistance in nude mouse MDR1 model of liver
neoplasm. World J Gastroenterol. 11:5621–5626. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee NY and Kang YS: The decrease of
paclitaxel efflux by pretreatment of interferon-γ and tumor
necrosis factor-α after intracerebral microinjection. Brain Res.
1499:158–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee G and Piquette-Miller M: Cytokines
alter the expression and activity of the multidrug resistance
transporters in human hepatoma cell lines; analysis using RT-PCR
and cDNA micro-arrays. J Pharm Sci. 92:2152–2163. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iqbal M, Ho HL, Petropoulos S, Moisiadis
VG, Gibb W and Matthews SG: Pro-inflammatory cytokine regulation of
P-glycoprotein in the developing blood-brain barrier. PLoS One.
7:e430222012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Belliard AM, Lacour B, Farinotti R and
Leroy C: Effect of tumor necrosis factor-alpha and interferon-gamma
on intestinal P-glycoprotein expression, activity, and localization
in Caco-2 cells. J Pharm Sci. 93:1524–1536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kreuser ED, Wadler S and Thiel E:
Biochemical modulation of cytotoxic drugs by cytokines: Molecular
mechanisms in experimental oncology. Recent Results Cancer Res.
139:371–382. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vacchelli E, Galluzzi L, Eggermont A,
Galon J, Tartour E, Zitvogel L and Kroemer G: Trial Watch:
Immunostimulatory cytokines. OncoImmunology. 1:493–506. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lejeune FJ and Rüegg C: Recombinant human
tumor necrosis factor: An efficient agent for cancer treatment.
Bull Cancer. 93:E90–E100. 2006.PubMed/NCBI
|
|
17
|
Baud V and Karin M: Signal transduction by
tumor necrosis factor and its relatives. Trends Cell Biol.
11:372–377. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karin M: How NF-kappaB is activated: The
role of the IkappaB kinase (IKK) complex. Oncogene. 18:6867–6874.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang TT, Kudo N, Yoshida M and Miyamoto
S: A nuclear export signal in the N-terminal regulatory domain of
IkappaBalpha controls cytoplasmic localization of inactive
NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA.
97:1014–1019. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bentires-Alj M, Barbu V, Fillet M, Chariot
A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V: NF-kappaB
transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takada Y, Kobayashi Y and Aggarwal BB:
Evodiamine abolishes constitutive and inducible NF-kappaB
activation by inhibiting IkappaBalpha kinase activation, thereby
suppressing NF-kappaB-regulated antiapoptotic and metastatic gene
expression, up-regulating apoptosis, and inhibiting invasion. J
Biol Chem. 280:17203–17212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang W, McLeod HL and Cassidy J:
Disulfiram-mediated inhibition of NF-kappaB activity enhances
cytotoxicity of 5-fluorouracil in human colorectal cancer cell
lines. Int J Cancer. 104:504–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ogretmen B and Safa AR: Negative
regulation of MDR1 promoter activity in MCF-7, but not in multidrug
resistant MCF-7/Adr, cells by cross-coupled NF-κ B/p65 and c-Fos
transcription factors and their interaction with the CAAT region.
Biochemistry. 38:2189–2199. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thompson JE, Phillips RJ,
Erdjument-Bromage H, Tempst P and Ghosh S: I kappa B-beta regulates
the persistent response in a biphasic activation of NF-kappa B.
Cell. 80:573–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hoffmann A, Levchenko A, Scott ML and
Baltimore D: The IkappaB-NF-kappaB signaling module: Temporal
control and selective gene activation. Science. 298:1241–1245.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmidt C, Peng B, Li Z, Sclabas GM,
Fujioka S, Niu J, Schmidt-Supprian M, Evans DB, Abbruzzese JL and
Chiao PJ: Mechanisms of proinflammatory cytokine-induced biphasic
NF-kappaB activation. Mol Cell. 12:1287–1300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ladner KJ, Caligiuri MA and Guttridge DC:
Tumor necrosis factor-regulated biphasic activation of NF-kappa B
is required for cytokine-induced loss of skeletal muscle gene
products. J Biol Chem. 278:2294–2303. 2003. View Article : Google Scholar
|
|
29
|
Gibson PR: Increased gut permeability in
Crohn's disease: Is TNF the link? Gut. 53:1724–1725. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Englund G, Jacobson A, Rorsman F,
Artursson P, Kindmark A and Rönnblom A: Efflux transporters in
ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp
(ABCB1). Inflamm Bowel Dis. 13:291–297. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Petrovic V, Teng S and Piquette-Miller M:
Regulation of drug transporters during infection and inflammation.
Mol Interv. 7:99–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blokzijl H, Vander Borght S, Bok LI,
Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA,
Moshage H, Jansen PL, et al: Decreased P-glycoprotein (P-gp/MDR1)
expression in inflamed human intestinal epithelium is independent
of PXR protein levels. Inflamm Bowel Dis. 13:710–720. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu L, Smythe AM, Stinson SF, Mullendore
LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV,
Boyd MR, et al: Multidrug-resistant phenotype of disease-oriented
panels of human tumor cell lines used for anticancer drug
screening. Cancer Res. 52:3029–3034. 1992.PubMed/NCBI
|
|
34
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: Evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ho EA and Piquette-Miller M: Regulation of
multidrug resistance by pro-inflammatory cytokines. Curr Cancer
Drug Targets. 6:295–311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ros JE, Schuetz JD, Geuken M, Streetz K,
Moshage H, Kuipers F, Manns MP, Jansen PL, Trautwein C and Müller
M: Induction of Mdr1b expression by tumor necrosis factor-alpha in
rat liver cells is independent of p53 but requires NF-kappaB
signaling. Hepatology. 33:1425–1431. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Um JH, Kang CD, Lee BG, Kim DW, Chung BS
and Kim SH: Increased and correlated nuclear factor-kappa B and Ku
auto-antigen activities are associated with development of
multidrug resistance. Oncogene. 20:6048–6056. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe
S, Mills GB and Unate H: Induction of human MDR1 gene expression by
2-acetyl aminofluorene is mediated by effectors of the
phosphoinositide 3-kinase pathway that activate NF-kappaB
signaling. Oncogene. 21:1945–1954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Arenzana-Seisdedos F, Thompson J,
Rodriguez MS, Bachelerie F, Thomas D and Hay RT: Inducible nuclear
expression of newly synthesized I kappa B alpha negatively
regulates DNA-binding and transcriptional activities of NF-kappa B.
Mol Cell Biol. 15:2689–2696. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Poppers DM, Schwenger P and Vilcek J:
Persistent tumor necrosis factor signaling in normal human
fibroblasts prevents the complete resynthesis of I kappa B-alpha. J
Biol Chem. 275:29587–29593. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gibson CJ, Hossain MM, Richardson JR and
Aleksunes LM: Inflammatory regulation of ATP binding cassette
efflux transporter expression and function in microglia. J
Pharmacol Exp Ther. 343:650–660. 2012. View Article : Google Scholar : PubMed/NCBI
|
